Open Your FREE Demat Account Now!

Supriya Lifescience Ltd. Share Price

NSE
BSE

NSE : SUPRIYA

BSE : 543434

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Low

₹958.80

High

₹994.85

Price Summary

Previous Close ₹985.20
Day's Range ₹958.80 - ₹994.85
Open ₹964.80
52 Week Range ₹545.50 - ₹1,085.00
Volume 3,26,713
Market Cap ₹0.01
Previous Close ₹984.85
Day's Range ₹958.10 - ₹994.35
Open ₹962.40
52 Week Range ₹545.65 - ₹1,085.50
Volume 14,355
Market Cap ₹0.01

Stocks Summary

Trade Value ( ₹ in Lacs) 3,199.53
Market Cap (₹ in Mn) 0.01
Dividend Yield(%) 0.10
Price/Earning (TTM) 39.96
TTM EPS (₹) 24.65
P/E Ratio 21.75
Book Value(₹) 6.49
PAT Margin (%) 22.86
Face Value (₹) 2.00
ROCE(%) 25.30
Trade Value ( ₹ in Lacs) 140.81
Market Cap (₹ in Mn) 0.01
Dividend Yield(%) 0.10
Price/Earning (TTM) 39.96
TTM EPS (₹) 24.65
P/E Ratio 21.75
Book Value(₹) 6.49
PAT Margin (%) 22.86
Face Value (₹) 2.00
ROCE(%) 25.30

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 1450.74 6964.85
Expenses N/A N/A
PBT 474.12 2484.81
Operating profit 0.0 0.0
Net profit 347.9 1879.58

Shareholding Pattern

Promoters (% Holding)

68.30%

Mutual funds (% Holding)

1.29%

Non-Institution (% Holding)

20.21%

FI/Banks/Insurance (% Holding)

2.40%

Government (% Holding)

0.00%

FII

6.18%

About Supriya Lifescience Ltd.

Founded 2008
Managing Director Saloni Satish Wagh
NSE Symbol SUPRIYA

Latest News

Sep
23
2026
EQUITY Posted on Sep 23rd 2026

Supriya Lifescience informs about updates

Further to Letters dated July 4, 2026 and September 2, 2026, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that on partial development in the matter wherein, the Hon'ble Court of Law has vide its judgment dated September 22 , 2026 passed an order in relation to the Company's application for provisional release of a consignment of 200 kg of Ketamine Hydrochloride covered under Shipping Bill No. 3780061 dated June 2, 2026. The Hon'ble Court has allowed the Company's application for provisional release of the said goods, subject to deposit of ₹72 lakh with the Assistant Commissioner of Customs, Export, ACC, Mumbai-III within one week from the date of the order; Clarified that the authorities may continue adjudication and criminal proceedings in accordance with law; and clarified that it shall be open to the concerned officer to follow the procedure under Section 52A of the NDPS Act. The Company continues to monitor the matter and will duly inform the Stock Exchanges on any further development, including any order passed by the Hon’ble Court, as and when received by the Company, in accordance with the applicable regulatory requirements.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
23
2026
EQUITY Posted on Jul 23rd 2026

Supriya Lifescience informs about newspaper advertisement

In terms of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Supriya Lifescience has informed that it enclosed copies of the newspaper advertisement extract for Postal Ballot Notice published in the newspapers, Financial Express (English Language) and Loksatta (Marathi Language).
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
4
2026
EQUITY Posted on Jul 4th 2026

Supriya Lifescience informs about disclosure

Pursuant to the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable laws, and in accordance with the Regulation 30 read with Para B of Part A of Schedule III of the Listing Regulations and SEBI circular dated July 13, 2023 SEBI Listing Regulations, Supriya Lifescience has informed that the investigation has been initiated yesterday against Sreekant Sreedharan, General Manager, Sales & Marketing officer of the Company by Special Investigation and Intelligence branch of Customs Department, subsequent to which judicial custody has been granted by CMM court till July 17, 2026. The Company remains committed to maintaining the highest standards of corporate governance and regulatory compliance. The Company is closely monitoring the developments in the case and any further material developments in the matter shall be disclosed to the stock exchanges in accordance with applicable laws and regulations. The details of the case as required under Circular no SEBI/HO/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023 are enclosed as Annexure A to the disclosure.

The above information is a part of company’s filings submitted to BSE.

Read More
Sep
25
2026
EQUITY Posted on Sep 25th 2026

Caplin Point Laboratories informs about proceedings of AGM

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Caplin Point Laboratories has informed that it enclosed the brief proceedings of the 35th Annual General Meeting of the Company held on Friday, September 25, 2026, at 10.00 AM (IST), through Video Conferencing/Other Audio-Visual Means. The details of the consolidated voting results of both the remote e-voting and e-voting during the AGM on all the resolutions will be filed separately, in the format prescribed under Regulation 44 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE. 

Read More
Sep
25
2026
EQUITY Posted on Sep 25th 2026

Vivo Bio Tech informs about closure of trading window

Vivo Bio Tech has informed that, pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 and Company’s Internal Code of Conduct to Regulate, Monitor and Report Trading by Directors, Promoters and Designated Persons of the Company, the Trading Window for dealing in the securities of the Company shall remain Closed for all insiders including Designated Persons and their immediate relatives from October 01, 2026 till the end of 48 hours after the declaration of the Unaudited Standalone and Consolidates Financial Results of the Company for the Second quarter ended September 30, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Supriya Lifescience Ltd. ?

The current share price of Supriya Lifescience Ltd. is ₹985.20 as of 2026-09-25.

The market capitalisation of Supriya Lifescience Ltd. is ₹7,926.35 as of 2026-09-25.

The 1-year return of Supriya Lifescience Ltd. is 243.90% as of 2026-09-25.

The P/E ratio of Supriya Lifescience Ltd. is 21.75 as of 2026-09-26.

The 52-week high and low of Supriya Lifescience Ltd. are ₹1,085.00 and ₹545.50, respectively, as of 2026-09-25.

The dividend yield of Supriya Lifescience Ltd. is 0.1015% as of2026-09-25.

You can buy Supriya Lifescience Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Supriya Lifescience Ltd. is Saloni Satish Wagh.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore